The tuberculosis treatment success rate for newly treated cases in the US is forecasted to remain stable, with a slight decline from 78% in 2024-2026 to 77% in 2027-2028. In 2023, the treatment success rate stood at 78%. This indicates minimal year-on-year variation, with a decline of approximately 1% by 2027. The Compound Annual Growth Rate (CAGR) suggests a steady trend without significant fluctuations over the five-year period.
Future trends to watch include advances in medical technology, drug resistance patterns, and public health initiatives, which could impact treatment success rates positively or negatively over time. Monitoring these factors will be crucial for forecasting and planning health policies effectively.
